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Long-term survival after surgical 
resection of locoregional gastric 
adenocarcinoma recurrence  
— a case report
ABSTRACT
Introduction. Recurrence is the leading cause of death of gastric cancer patients after curative resection. This 
report describes a 44-year-old woman with gastric adenocarcinoma and surgically resected locoregional recur-
rence, who has survived for more than 13 years after diagnosis.
Case report. A 33-year-old woman was admitted to the Gastroenterology Clinic with an episode of epigastric 
pain and minor weight loss. Two years earlier she had been diagnosed with gastric adenocarcinoma G2 of the 
antrum, pT2N1M0 (IIA) stage. She had undergone total gastrectomy with D2 lymphadenectomy and Roux-en-Y 
anastomosis followed by postoperative chemotherapy. Further diagnostic investigation after two years revealed 
the presence of metastatic cancer in the gastric bed. An explorative laparotomy was performed, and the surgeons 
successfully excised the enlarged lymph node. Post-operative pathologic examination proved gastric cancer 
metastasis. Since April 2007 the patient has stayed recurrence-free, and there have been no signs of recurrence 
on either US or CT scan, as of April 2018. This patient represents a rare case of long-term survival of recurrent 
gastric adenocarcinoma successfully treated with surgery despite particularly poor prognosis.
Conclusions. Surgery for gastric cancer recurrence is a valuable treatment in chosen patients, provided it is 
performed by a team of specialised surgeons.
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Introduction
Gastric cancer is the fifth most common cancer 
worldwide and the third leading cause of cancer-related 
deaths [1]. Gastric adenocarcinoma comprises 95% of 
malignant tumours of the stomach. While its incidence is 
gradually decreasing, the prognosis for the patients after 
curative gastrectomy is still poor. Recurrent tumour 
develops in most cases and often makes gastric cancer 
incurable [2–4]. Recurrences after curative resection for 
gastric carcinoma have been categorised as locoregional 
recurrence, peritoneal recurrence, and distant (including 
haematogenous) metastasis [5]. Although there is no 
clear consensus on the treatment of choice for recur-
rent gastric cancer, there have been a few reports on the 
relative effectiveness of surgical treatment in selected 
patients [6]. Here, we present a rare case of long-term 
survival (over 11 years after secondary resection of 
locoregional recurrence) of gastric adenocarcinoma.
Case report
A 33-year-old woman reported to the Oncology Cen-
tre with an episode of abdominal pain and minor weight 
loss. On examination she was in good overall condition, 
without lymphadenopathy, and the abdomen was tender 
and painless, with no abnormal masses. Ultrasound re-
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vealed a tumour in the gastric bed. Fine-needle biopsy 
confirmed the presence of metastatic adenocarcinoma 
in a lymph node located around the pancreatic head.
The patient had a relevant medical history. Two 
years earlier, in 2004, she had undergone a total 
gastrectomy due to gastric cancer. Back then, she 
had presented with similar symptoms of unabating 
epigastric pain. Endoscopic findings had revealed an 
exophytic mass with central ulceration spreading over 
the lesser curvature and the anterior gastric wall, and 
the diagnosis of gastric adenocarcinoma G2, mixed 
type by Lauren classification, had been confirmed 
on histopathologic examination. On November 11, 
2004, a total gastrectomy with D2 lymphadenectomy 
had been performed (R0 resection), with Roux-en-Y 
reconstruction of the gastrointestinal tract continuity. 
Pathologic examination revealed that the tumour was 
pT2N1M0 stage (clinical stage IIA) with two positive 
out of 30 excised lymph nodes. The patient had then 
received postoperative chemotherapy in the form of 
four cycles of FAM regimen (Fluorouracil-Adriamy-
cin-Mitomycin).
Having considered the available treatment op-
tions, the surgeons decided to perform an explora-
tive laparotomy and the malignant lymph node was 
excised 28 months after the primary resection. She 
has not received perioperative chemotherapy. Both 
the serum carcinoembryonic antigen (CEA) and the 
carbohydrate antigen 19-9 (CA 19-9) levels were 
within the normal range immediately after the sur-
gery and at follow-up. Post-operative examination 
of the excised lymph node proved gastric cancer 
metastasis (Fig. 1 A–C). Since April 2007 the patient 
has remained recurrence-free, and there have been 
no signs of recurrence on either US or CT scan, as 
of April 2018.
Figure 1A. Hematoxylin and eosin stain (H&E). Cytology. Lymph 
node metastasis
A
Figure 1C. Hematoxylin and eosin stain (H&E). Solid nests of 
gastric cancer in the metastatic lymph node
B
Figure 1B. Hematoxylin and eosin stain (H&E). Glandular 
structures of gastric cancer in the metastatic lymph node
C
Discussion
Despite the improvements in diagnosis and surgical 
techniques, the prognosis and survival of gastric adeno-
carcinoma patients are significantly dependent on the 
stage of disease at the time of diagnosis. According to the 
American Joint Committee on Cancer (AJCC) survival 
data, for a cancer staged as in our case, treated with sur-
gery and perioperative therapy, three-year and five-year 
survival are, respectively, 54.8% and 46.3% [1]. One major 
problem is that no effective therapy for recurring gastric 
cancer exists at present. Numerous studies try to evaluate 
the patterns and pre-operative predictive factors of recur-
rence. It seems that valid strategies to prevent postsurgical 
recurrence are curative resection, standard lymphadenec-
tomy, and perioperative chemotherapy. Current ESMO 
recommendations include perioperative chemotherapy 
for patients with ≥ stage IB gastric cancer and adjuvant 
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therapy only if no chemotherapy was administered preope-
ratively [7]. The mean time to recurrence for locoregional 
recurrence was reported to be 26.4–28.1 months [8, 9]. In 
the presented case, it was 27 months after the primary 
surgery when the recurrence was detected.
While locoregional recurrence accounts for around 
25% of all recurrences, the most common recurrence 
pattern is peritoneal recurrence (around 40% of cases). 
Haematogenous metastasis is the third most common 
pattern, with liver being a typical location [2]. Locore-
gional recurrent gastric cancer is commonly treated with 
chemotherapy only. Recurrences are rarely treatable 
with surgery and there are no proper indications for 
those patients. There are no predictive clinicopatho-
logical indicators for surgical resection, other than 
resectability [2, 8, 10]. However, when surgical resection 
is performed, the expected five-year survival rate was 
reported to be 20%, and the prognosis is even better 
if the resection was complete [2, 3, 8]. Our patient has 
experienced over 11 years recurrence-free.
Kong et al. found the two-year cumulative survival 
rates to be significantly better for resection of the re-
currence plus chemotherapy than for chemotherapy 
only (23.8% vs. 1.2%, p < 0.001) [2]. Other studies also 
report generally longer survival time when surgery is 
performed along with chemotherapy [5, 6]. For any given 
patient, appropriateness of extensive resection should 
be assessed by a multidisciplinary assessment team. If 
the perioperative risk is low, surgery seems justified 
because no other therapy is effective enough. There are 
also numerous reports of long-term survival after surgery 
of recurrent gastric cancer with liver metastasis. Kiyasu 
described a case of over 18-year survival after gastric ad-
enocarcinoma resection and subsequent liver metastases 
resection 30 months later [11]. Ambiru et al. reviewed 
the cases of six patients who survived longer than five 
years after curative excision of the stomach and liver [12].
Conclusions
Surgery for gastric cancer recurrence is a valuable 
treatment in chosen patients, provided it is performed 
by a team of specialised surgeons. Considering the 
high mortality and ineffectiveness of other therapies 
for recurrent gastric cancer, standardised indications 
for surgery should be elaborated. Further studies as-
sessing the validity and effectiveness of this method 
are also needed.
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